Reference number : 236-2014-2015-Q2-00093, amendment number : , agreement type : G, recipient legal name : RETNAKARAN, Ravi R, recipient country : CA, recipient province : ON, recipient city : Toronto, recipient postal code : M5G 1X5, program name english : nan, program name french : nan, program purpose english : nan, program purpose french : nan, agreement title english : nan, agreement title french : nan, agreement number : nan, agreement value : 366920.0, agreement start date : 2014-10-01, agreement end date : 2018-03-31, description english : Exenatide and Insulin Glargine Combination Therapy for the Preservation of Pancreatic Beta-cell Function in Early Type 2 Diabetes: A Randomized Controlled Trial, description french : Exenatide and Insulin Glargine Combination Therapy for the Preservation of Pancreatic Beta-cell Function in Early Type 2 Diabetes: A Randomized Controlled Trial, expected results english : nan, expected results french : nan, additional information english : Grant or Award spanning more than one fiscal year.
(2014-15 to 2017-18), additional information french : Subvention ou bourse octroyée s'appliquant à plus d'un exercice financier.
(2014-15 à 2017-18), owner organization : cihr-irsc, owner organization title : Canadian Institutes of Health Research | Instituts de recherche en santé du Canada